We are a team of twenty scientists engineers, including nine PhDs, has for the past seven years been researching and developing a Bioorthogonal alternative to PCR. With minimal sample preparation, the Altratech product and assay can rapidly detect and quantify molecular targets from any sample. The technology brings together nanotechnology, CMOS semiconductor technology and novel PNA chemistry to produce a unique and powerful assay. The assay named Molecular Detection by Proxy is a bead-based technology coupled with ultra-sensitive capacitance detection.

We are creating an infrastructure of technology and data to manage contagious viral diseases, important for the future of decentralised connected healthcare and wellbeing.

Based on the novel Detection by Proxy concept, Altratech has developed the next generation of molecular detection. The technology enables any person, anywhere, to rapidly and accurately measure and quantify viral RNA, DNA, antigen, or antibody samples.

Our first product will enable at-home detection of SARS-CoV-2 RNA and multiplexed identification of Variants-of-Concern (VOC) from a self-collected saliva sample with the sensitivity and specificity of a laboratory test. The safe sealed test cartridge will eliminate the risks due to sample handling and shipping to laboratories. It addresses the post-pandemic ongoing unmet needs of a home SARS-CoV-2 viral RNA test, and real-time field surveillance.